Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 23, 2022 - Issue 12
Submit an article Journal homepage
1,572
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Additional perspective on cariprazine and negative symptoms

Joshua T. Kantrowitza Division of Experimental Therapeutics, New York State Psychiatric Institute, New York, NY, USA;b Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA;c Schizophrenia Research Center, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1127-7016View further author information
ORCID Icon
Pages 1469-1470 | Received 06 Aug 2021, Accepted 12 Aug 2021, Published online: 21 Aug 2021

References

  • Nemeth G, Dombi ZB, Laszlovszky I, et al. Addressing negative symptoms of schizophrenia pharmacologically with cariprazine: evidence from clinical trials, a real-world study, and clinical cases. Expert Opin Pharmacother. 2021.
  • Kantrowitz JT. How do we address treating the negative symptoms of schizophrenia pharmacologically? Expert Opin Pharmacother. 2021 Jun;16:1–3.
  • Nemeth G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 Mar 18;389(10074):1103–1113.
  • Galderisi S, Kaiser S, Bitter I, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021 Mar 17;64(1):e21.
  • Earley W, Guo H, Daniel D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res. 2019 Feb;204:282–288.
  • Kopelowicz A, Zarate R, Tripodis K, et al. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry. 2000 Jun;157(6):987–993.
  • James S, Kapugama C, Al-Uzri M. Use of aripiprazole long acting injection in negative symptoms of schizophrenia. Case Rep Psychiatry. 2016;2016:7912083.
  • Loebel A, Cucchiaro J, Silva R, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. Eur Psychiatry. 2015 Jan;30(1):26–31.
  • Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs. 2017 May;31(5):373–388.
  • Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018 Oct;268(7):625–639.
  • Turner EH, Knoepflmacher D, Shapley L. Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US food and drug administration database. PLoS Med. 2012;9(3):e1001189.
  • Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008 Mar;29(2):109–113.
  • Leucht S, Davis JM. Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. Lancet. 2017 Mar 18;389(10074):1077–1078.
  • Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939–951.
  • Earley W, Durgam S, Lu K, et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol. 2017 Nov;32(6):319–328.
  • Quill TE, Holloway R. Time-limited trials near the end of life. JAMA. 2011 Oct 5;306(13):1483–1484.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.